Cargando…

Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment

PURPOSE: It is not known if mammographic breast compression of a primary tumor causes shedding of tumor cells into the circulatory system. Little is known about how the detection of circulating biomarkers such as circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) is affected by breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Förnvik, Daniel, Aaltonen, Kristina E., Chen, Yilun, George, Anthony M., Brueffer, Christian, Rigo, Robert, Loman, Niklas, Saal, Lao H., Rydén, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661025/
https://www.ncbi.nlm.nih.gov/pubmed/31236809
http://dx.doi.org/10.1007/s10549-019-05326-5
_version_ 1783439397259051008
author Förnvik, Daniel
Aaltonen, Kristina E.
Chen, Yilun
George, Anthony M.
Brueffer, Christian
Rigo, Robert
Loman, Niklas
Saal, Lao H.
Rydén, Lisa
author_facet Förnvik, Daniel
Aaltonen, Kristina E.
Chen, Yilun
George, Anthony M.
Brueffer, Christian
Rigo, Robert
Loman, Niklas
Saal, Lao H.
Rydén, Lisa
author_sort Förnvik, Daniel
collection PubMed
description PURPOSE: It is not known if mammographic breast compression of a primary tumor causes shedding of tumor cells into the circulatory system. Little is known about how the detection of circulating biomarkers such as circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) is affected by breast compression intervention. METHODS: CTCs and ctDNA were analyzed in blood samples collected before and after breast compression in 31 patients with primary breast cancer scheduled for neoadjuvant therapy. All patients had a central venous access to allow administration of intravenous neoadjuvant chemotherapy, which enabled blood collection from superior vena cava, draining the breasts, in addition to sampling from a peripheral vein. RESULTS: CTC and ctDNA positivity was seen in 26% and 65% of the patients, respectively. There was a significant increase of ctDNA after breast compression in central blood (p = 0.01), not observed in peripheral testing. No increase related with breast compression was observed for CTC. ctDNA positivity was associated with older age (p = 0.05), and ctDNA increase after breast compression was associated with high Ki67 proliferating tumors (p = 0.04). CTCs were more abundant in central compared to peripheral blood samples (p = 0.04). CONCLUSIONS: There was no significant release of CTCs after mammographic breast compression but more CTCs were present in central compared to peripheral blood. No significant difference between central and peripheral levels of ctDNA was observed. The small average increase in ctDNA after breast compression is unlikely to be clinically relevant. The results give support for mammography as a safe procedure from the point of view of CTC and ctDNA shedding to the blood circulation. The results may have implications for the standardization of sampling procedures for circulating tumor markers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-019-05326-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6661025
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-66610252019-08-07 Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment Förnvik, Daniel Aaltonen, Kristina E. Chen, Yilun George, Anthony M. Brueffer, Christian Rigo, Robert Loman, Niklas Saal, Lao H. Rydén, Lisa Breast Cancer Res Treat Clinical Trial PURPOSE: It is not known if mammographic breast compression of a primary tumor causes shedding of tumor cells into the circulatory system. Little is known about how the detection of circulating biomarkers such as circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) is affected by breast compression intervention. METHODS: CTCs and ctDNA were analyzed in blood samples collected before and after breast compression in 31 patients with primary breast cancer scheduled for neoadjuvant therapy. All patients had a central venous access to allow administration of intravenous neoadjuvant chemotherapy, which enabled blood collection from superior vena cava, draining the breasts, in addition to sampling from a peripheral vein. RESULTS: CTC and ctDNA positivity was seen in 26% and 65% of the patients, respectively. There was a significant increase of ctDNA after breast compression in central blood (p = 0.01), not observed in peripheral testing. No increase related with breast compression was observed for CTC. ctDNA positivity was associated with older age (p = 0.05), and ctDNA increase after breast compression was associated with high Ki67 proliferating tumors (p = 0.04). CTCs were more abundant in central compared to peripheral blood samples (p = 0.04). CONCLUSIONS: There was no significant release of CTCs after mammographic breast compression but more CTCs were present in central compared to peripheral blood. No significant difference between central and peripheral levels of ctDNA was observed. The small average increase in ctDNA after breast compression is unlikely to be clinically relevant. The results give support for mammography as a safe procedure from the point of view of CTC and ctDNA shedding to the blood circulation. The results may have implications for the standardization of sampling procedures for circulating tumor markers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-019-05326-5) contains supplementary material, which is available to authorized users. Springer US 2019-06-24 2019 /pmc/articles/PMC6661025/ /pubmed/31236809 http://dx.doi.org/10.1007/s10549-019-05326-5 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Trial
Förnvik, Daniel
Aaltonen, Kristina E.
Chen, Yilun
George, Anthony M.
Brueffer, Christian
Rigo, Robert
Loman, Niklas
Saal, Lao H.
Rydén, Lisa
Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
title Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
title_full Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
title_fullStr Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
title_full_unstemmed Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
title_short Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
title_sort detection of circulating tumor cells and circulating tumor dna before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661025/
https://www.ncbi.nlm.nih.gov/pubmed/31236809
http://dx.doi.org/10.1007/s10549-019-05326-5
work_keys_str_mv AT fornvikdaniel detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT aaltonenkristinae detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT chenyilun detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT georgeanthonym detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT bruefferchristian detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT rigorobert detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT lomanniklas detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT saallaoh detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment
AT rydenlisa detectionofcirculatingtumorcellsandcirculatingtumordnabeforeandaftermammographicbreastcompressioninacohortofbreastcancerpatientsscheduledforneoadjuvanttreatment